First AId 2CK > Pulmonary > Flashcards

Pulmonary Flashcards

(56 cards)

Study These Flashcards
1
Q

Systemic Sarcoidosis

A
  • multi-system dx of unknown etiology with NONCASEATING GRANULOMAS
  • often found in African-American females and North European Caucasians
  • often arises in 3rd or 4th decade of life
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Systemic Sarcoidosis: Hx and PE

A

can present with fever, cough, malaise, weight loss, dyspnea, and arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Systemic Sarcoidosis: Dx

A

CXR/CT: lymphadenopathy and nodules used to stage disease
Biopsy: lymph node biopsy or T-VATS lung biopsy shows noncaseating granulomas
PFTS: show restrictive/obstructive patter and decr. diffused capacity
- increased serum ACE levels, hypercalcemia, increased alk phos, lymphopneia, CN defcitic, arrhythmias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Systemic Sarcoidosis: Tx

A

Systemic corticosteroids indicared for deteriorating respiratory fxn, constitutional sx, hypercalcemia, or extrathoracic organ involvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Obstructive Lung Disease

A
  • characteried by airway narrowing

- OLD restricts aire movement and cause air trapping

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Etiology of Obstructive Lung Disease

A 
ABCT
Asthma
Bronchiectasis
Cystic fibrosis/ COPD
Tracheal or bronchial obstruction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Asthma

A
  • reversible airway obstruction secondary to bronchial hyperactivity, airway inflammation, mucous plugging and smooth muscle hypertrophy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Asthma: Hx and PE

A
  • persists with cough, episodic wheezing, dyspnea and/or chest tightness
  • exam shows wheezing, prolonged expiratory duration (decr. I/E ration), accessory muscle use
  • decreased breath sounds and decreased SpO2 are late signs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Asthma: Dx

A
  • ABGs: mild hypoxia and respiratory alkalosis
  • Spirometry: decreased FEV1/FVC
  • increased residual volume and total lung capacity
  • CBC: possible eosinophilia
  • CXR: hyperinflation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Methacholine challenged

A
  • tests for bronchial hyperresponsive

- useful when PFTs are normal but still suspect asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Asthma: Tx

A

Avoid triggers (allergens, URIs, cold air, exercise, drugs, and stress)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Tx of acute asthma

A
  • Oxygen
  • Bronchodilating agents (inhaled B2 agonists - first line therapy)
  • Ipatropium (never used alone for asthma)
  • Systemic corticosteroids, magnesium for severe exacerbations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Tx for chronic asthma

A
  • administer long acting bronchodilators and/or inhaled corticosteroids
  • can also use systemic corticosteroids, cromolyn or rarely theophylline
  • Montelukas and other leukotriene antagonist s are oral adjuncts to inhalant therapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

B-2 agonists

A

albuterol or salmeterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Albuterol

A
  • short acting B-2 agonists

- relaxes bronchial smooth muscle (B 2 adrenoreceptors)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Salmeterol

A
  • long acting B-2 agonist for prophylaxis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Inhaled corticosteroids

A
  • first line treatment for long term control of asthma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Beclomethasone, prednisone

A

inhibit synthesis of virtually all cytokines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Muscarinic antagonists

A

(e. g. ipratroprium)

- competitively blocks muscarinic receptors, preventing bronchospasm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Methylxanthines

A

(e. g. theophylline)
- likely causes bronchodilation by inhibiting phosphodiesterae, thereby decreasing cAMP hydrolysis and increasing cAMP levels
- limited use b/c of narrow therapeutic-toxic index (cardiotoxcity, neurotoxicity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Cromolyn

A
  • prevents release of vasoactive mediators from mast cells
  • useful for exercise induced bronchospasm
  • EFFECTIVE FOR PROPHYLAXIS OF ASTHMA
  • not effective during acute asthma attack
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Antileukotrienes

A

(e.g. zileuton, monteleukast, zafirlukast)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Zileuton

Study These Flashcards
A

5- lipoxygenase pathway inhibitor. Blocks conversion of arachodonic acid to leukotriens

24
Q

Monteleukast, zafirleukast

Study These Flashcards
A
  • block leukotriene receptors
25
Meds for ASTHMA exacerbation
``` ASTHMA Albuterol Salmeterol Theophylline (rare) Humidified oxygen Magnesium (for severe exacerbations) Anticholingerics ```
26
10 yr old with hx of asthma on daily fluticasone has been using an albuterol inhaler once a day for several weeks. What changes should be made to current regimen?
Moderate persistent asthma w/ daily symptoms | - may benefit from long acting B-2 agonist (salmeterol) for prevention of symptoms
27
Mild intermittent asthma
``` < 2 days/ week < 2 nights/month FEV > 80% - no daily meds - prn short acting bronchodilator (albuterol) ```
28
Mild persistent asthma
``` > 2 / weeks but < 1/ day > 2 nights/ month FEV > 80 % - daily low dose inhaled corticosteroids - prn short acting B2 agonist ```
29
Moderate persistent asthma
``` Daily > 1 night/ week FEV 60 - 80% low to medium dose inhaled corticosteroids + long acting inhaled B2 agonist prn short-acting bronchodilator ```
30
Severe persistent asthma
``` Continual, frequent FEV < 60 % High dose inhaled corticosteroids + long acting B2 agonists - possible PO corticosteroids PRN short-acting bronchodilator ```
31
Bronchiectasis
- disease caused by cycles of infection and inflammation in the bronchi/bronchioles that lead to fibrosis, remodeling and PERMANENT DILATION OF BRONCHI
32
Bronchiectasis: Hx and PE
- presents with chronic cough accompanied by frequent bouts of yellow or green sputum production, dyspnea, and possible hemoptysis and halitosis - exam reveals rales, wheezes, rhonchi, purulent mucous and occasional hemoptysis
33
Conditions associated with bronchiectasis
- Pulmonary infxns - Hypersensitivity - Cystic fibrosis - Immunodeficiency - Localized airway obstruction
34
Bronchiectasis: Dx
CXR: shows increased bronchovascular marking and tram lines (parallel lines outlinting dilating bronchi ) CT: Dilated airways and balloon cysts are seen at end of bronchus (mostly lower lobes)
35
Bronchiectasis: Tx
- Abx for bacterial infections - maintain bronchopulmonary hygiene (cough control, postural drainage) - consider lobectomy for localized disease or lung transplantation
36
Chronic Obstructive Pulmonary Disease (COPD)
- disease with decreased lung fxn associated with airflow obstruction - secondary to chronic bronchitis or emphysema
37
Chronic Bronchitis
- productive cough for > 3 months per year for 2 consecutive years
38
Emphysema
terminal airway destruction and destruction that may be secondary to smoking (centrilobular) or to alpha-1 antitrypsin deficient (panlobular)
39
Emphysema: Hx and PE
"Pink puffer": dyspnea, pursed lips, minimal cough, decreased breath sounds - late hypercarbia/hypoxia - tend to have thin wasted apperance - few exacerbations in between episodes
40
Chronic bronchitis
"Blue bloater": Cyanosis with mild dyspnea, productive cough | - often overweight with peripheral edema, rhonchi and early signs of hypercarbia/hypoxia
41
COPD: Dx
CXR: Hyperinflated lungs: decreased lung markings with flat diaphragms and thin heart/mediastiunum - parenchymal bullae or subpleural blebs ABGS: hypoxemia with acute or chronic respiratory acidosis - consider gram stain or sputum culture if pt has fecer or productive cough
42
COPD: PFTs
Decreased FEV1/FVC - normal or decreased FVC - increased TLC (emphysema, asthma) - decreased DLco (emphysema)
43
Acute COPD exacerbation Treatment
- Oxygen - Inhaled B2 agonists - Anticholingerics (ipatropium, tiotroprium) - IV and/or inhaled corticosteroids - Abx * * Severe cases may need BiPap**
44
Chronic COPD exacerbation treatment
- Smoking cessation, inhaled B2 agonists, anticholingerics (tiotroprium), systemic/inhaled corticosteroids - Supplemental oxygen if resting PaO2 < 55 mm Hg or SaO2 < 80% or has cor pulmonale, pulm HTN, or hematocrit < 35% - Give pneumococcal and flu vaccines
45
COPD Treatment
``` COPD Corticosteroids Oxygen Prevention (stop smoking/ flu + pneumoccocal vaccines) Dilators (B2 agonists, anticholinergic) ```
46
Restrictive Lung Disease
- loss of lung compliance | - result in increased lung stffness and decreased lung expansion
47
Causes of atypical pneumonia
- Mycoplasma - Legionella - Chlamydia
48
Causes of nosocomial pneumonia
- GNRs - Staphylcoccus - Anaerobes
49
Causes of immunocompromised pneumonia
- Staphylcoccocus - Gram positive rods - Fungi (e.g. aspergillous) - P. jiroveci (esp with HIV) - Mycobacteria
50
Causes of aspiration pneumonia
Anaerobes
51
Causes of pneumonia in alcoholics/IV drug users
S. pneumoniae Klebsuella Staphylococcus
52
Causes of cystic fibrosis pneumonia
Pseudomonas Burkholderia S. aureus Mycobacteria
53
Causes of pneumonia in COPD
H. influenzae Moraxella catarrhalis S. pneumoniae
54
Causes of post-viral pneumonia
S. pneumonoia Staphylococcus H. influenzae
55
Causes of pneumonia in neonates
Group B Strep | E. coli
56
Causes of recurrent pneumnoa
``` Obstruction Bronchogenic carcinoma Lymphoma Wegener's granulomatosis Immunodeficiency Unusual organisms (e.g. Nocardia, Coxiella burnetti, Aspergillus, Pseudomona ```
First AId 2CK
flashcards
Decks in class (22)
# Cards
Brainscape helps you reach your goals faster, through stronger study habits.
© 2026 Bold Learning Solutions. Terms and Conditions